CDK8 - Network of Cancer Research

Breast Cancer Triple-Negative Breast Cancer

LL-K8-22 is a CDK8-cyclin C Dual Degrader for TNBC Research

Louis Gilman May 9, 2023

CDK8 is a transcription-associated cyclin-dependent protein kinase (CDK) and also is a colorectal cancer oncogene. Cyclin C is a member of the cyclin family of proteins. Besides, Cyclin C interacts…

Lymphoma PROTAC

JH-XI-10-02 is a Highly Potent and Selective PROTAC CDK8 Degrader

Louis Gilman January 23, 2021

PROteolysis Targeting Chimeras (PROTACs) regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets. PROTACs show better selectivity compared to classic inhibitors. PRTOACs…

Cancer

LL-K8-22 is a CDK8-cyclin C Dual Degrader for TNBC Research

JH-XI-10-02 is a Highly Potent and Selective PROTAC CDK8 Degrader

You Missed

Irinotecan is a Topoisomerase I Inhibitor for Colorectal Cancer Research

Copanlisib is a Pan-class I PI3K Inhibitor for Lymphoma Resaerch

Erlotinib is an EGFR TKI for NSCLC and Pancreatic Cancer Research

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research